Invivyd (IVVD) Accumulated Expenses (2020 - 2026)
Invivyd's (IVVD) quarterly Accumulated Expenses came in at $19.9 million in Q2 2026, down 21.54% on a YoY basis from $25.3 million in Q2 2025, and up 4.21% quarter-over-quarter from $19.1 million in Q4 2025.
Analysis
Invivyd (IVVD) Accumulated Expenses (2020 - 2026) Analysis & Trends
Invivyd (IVVD) has reported Accumulated Expenses for 7 consecutive years, with $19.9 million the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Accumulated Expenses fell 21.54% year-over-year to $19.9 million; the trailing twelve-month figure through Jun 2026 stood at $19.9 million (down 21.54% YoY), and the FY2025 full-year result was $19.1 million, down 62.04% from the prior year.
- Accumulated Expenses improved to $19.9 million in Q2 2026 per IVVD's latest filing, from $19.1 million in the prior quarter.
- Across five years, Accumulated Expenses topped out at $76.5 million in Q1 2022 and bottomed at $14.5 million in Q1 2023.
- Historically, Accumulated Expenses has averaged $34.0 million across 5 years, with a median of $26.8 million in 2024.
- The sharpest annual moves came in 2023 and 2024: Accumulated Expenses plunged 81.05% in 2023, then soared 272.23% in 2024.
- Over 5 years, Accumulated Expenses stood at $21.9 million in 2022, then jumped by 86.48% to $40.9 million in 2023, then gained by 22.85% to $50.2 million in 2024, then sank by 62.04% to $19.1 million in 2025, then gained by 4.21% to $19.9 million in 2026.
- According to Business Quant data, Accumulated Expenses over the past three periods registered $19.9 million, $19.1 million, and $25.3 million for Q2 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 236.37 Bn | 222.38 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 187.38 Bn | 184.12 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 138.36 Bn | 130.51 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 85.09 Bn | 77.10 Bn | 3.93 Bn |
| 5 | Argenx Se | 63.93 Bn | 58.75 Bn | 1.37 Bn |
| 6 | Moderna | 58.07 Bn | 52.94 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 35.59 Bn | 32.28 Bn | 992.69 Mn |
| 8 | Biogen | 32.63 Bn | 31.34 Bn | 1.96 Bn |
| 9 | Insmed | 27.57 Bn | 26.41 Bn | 358.27 Mn |
| 10 | Invivyd | 244.65 Mn | 84.57 Mn | 13.01 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 19.86 Mn |
| Dec 31, 2025 | 19.05 Mn |
| Sep 30, 2025 | 25.28 Mn |
| Jun 30, 2025 | 25.31 Mn |
| Mar 31, 2025 | 39.93 Mn |
| Dec 31, 2024 | 50.20 Mn |
| Sep 30, 2024 | 59.40 Mn |
| Jun 30, 2024 | 26.82 Mn |
| Mar 31, 2024 | 34.00 Mn |
| Dec 31, 2023 | 40.86 Mn |
| Sep 30, 2023 | 15.96 Mn |
| Jun 30, 2023 | 26.74 Mn |
| Mar 31, 2023 | 14.50 Mn |
| Dec 31, 2022 | 21.91 Mn |
| Sep 30, 2022 | 28.97 Mn |
| Jun 30, 2022 | 52.62 Mn |
| Mar 31, 2022 | 76.54 Mn |
| Dec 31, 2021 | 56.28 Mn |
| Sep 30, 2021 | 35.49 Mn |
| Jun 30, 2021 | 27.18 Mn |